Stockreport

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting [Yahoo! Finance]

Belite Bio, Inc - American Depositary Shares  (BLTE) 
PDF Stargardt disease patients provides further support for the potential of Tinlarebant to slow and potentially halt lesion growth In 5 of 12 subjects (42%) with known pa [Read more]